We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CRDA:LSECroda International Plc Analysis

Data as of 2026-06-13 - not real-time

£3,052.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Technical outlook: The share price is comfortably above the 20‑day, 50‑day and 200‑day moving averages, with a bullish MACD crossover and an RSI that has risen above the 60‑point threshold, signalling continued upward momentum. However, trading volume has been on a downtrend, which could limit short‑term price thrusts.
Fundamental backdrop: Croda delivers solid revenue growth of roughly 4% and maintains a healthy gross margin near 44%, but its operating margin remains slightly negative, and the current dividend payout exceeds earnings, raising concerns about sustainability. Forward earnings estimates compress the price‑to‑earnings multiple dramatically, and a discounted cash‑flow model indicates an upside of around 18% versus the current market price, aligning with a consensus “buy” rating and target prices above today’s level.
Risk considerations: While the stock exhibits high 30‑day price volatility, its beta is low, suggesting limited market‑wide risk. The specialty chemicals sector faces moderate regulatory scrutiny, but Croda’s geographic diversification across Europe, the Americas and Asia mitigates location‑specific risks. Liquidity appears adequate despite the recent volume dip.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above SMAs, MACD bullish)
  • Decreasing trading volume limiting immediate upside
  • Proximity to short‑term resistance level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF‑derived upside of roughly 18% to fair value
  • Forward earnings compression reducing P/E to a more reasonable level
  • Consensus analyst targets above current price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified global footprint reducing geographic concentration risk
  • Strong gross margins supporting sustainable profitability
  • Potential for dividend policy adjustment improving payout sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth3.90%
Profit Margin3.65%
P/E Ratio69.4
ROE2.88%
ROA2.10%
Debt/Equity31.63
P/B Ratio1.9
Op. Cash Flow£286.5M
Free Cash Flow£65.9M

Technical Analysis

TrendBullish
RSI61.2
Support£2,700.00
Resistance£3,115.59
MA 20£2,942.55
MA 50£2,914.10
MA 200£2,805.43
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value£364.60
Target Price£3,615.36
Upside/Downside18.46%
GradeUndervalued
TypeBlend
Dividend Yield3.64%

Risk Assessment

Beta0.32
Volatility24.70%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.